Optimind Pharma Corp.
OMND
CNSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 19.30K | 30.00K | 11.80K | 20.60K | 19.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.30K | 30.00K | 11.80K | 20.60K | 19.50K |
| Cost of Revenue | 7.90K | 9.90K | 8.80K | 1.80K | 9.70K |
| Gross Profit | 11.40K | 20.10K | 3.00K | 18.80K | 9.80K |
| SG&A Expenses | 16.40K | 76.90K | 72.90K | 119.50K | 75.00K |
| Depreciation & Amortization | -- | -- | -- | 0.00 | 3.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.20K | 86.80K | 81.70K | 121.30K | 88.40K |
| Operating Income | -4.90K | -56.80K | -69.90K | -100.70K | -68.80K |
| Income Before Tax | -6.60K | -60.30K | -71.50K | -532.00K | -76.50K |
| Income Tax Expenses | -- | -- | -- | -6.50K | -- |
| Earnings from Continuing Operations | -6.60K | -60.30K | -71.50K | -525.50K | -76.50K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.60K | -60.30K | -71.50K | -525.50K | -76.50K |
| EBIT | -4.90K | -56.80K | -69.90K | -100.70K | -68.80K |
| EBITDA | -- | -- | -- | -98.10K | -66.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 109.79M | 109.22M | 116.89M | 103.98M | 98.09M |
| Average Diluted Shares Outstanding | 109.79M | 109.22M | 116.89M | 103.98M | 98.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
